Hayflick Therapeutics

Company

Hayflick Therapeutics develops one asset, in human trials (topical rapamycin). Mostly programs acting on MTOR.

1
Asset
Furthest stage
Human trials
0
Trials
0
Signals

Pipeline

1
  • topical rapamycin

    Localized, micro-dose mTOR suppression reduces markers of cellular aging in skin without systemic exposure.

    Human trials, MTOR

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • People8
  • Signals1

Intelligence